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Abstract: Hepatitis is defined as inflammation of the liver and is commonly due to infection with The hepatotropic viruses –
hepatitis A, B, C, D and E. Hepatitis carries one of the highest disease burdens globally and has caused significant morbidity and
mortality among different patient populations. Clinical presentation varies from asymptomatic or acute flu-like illness to acute liver
failure or chronic liver disease, characterized by jaundice, hepatomegaly and ascites among many other signs. Eventually, this can
lead to fibrosis (cirrhosis) of the liver parenchyma and carries a risk of development into hepatocellular carcinoma. Hepatitis B and
C are most notorious for causing liver cirrhosis; in 2019, an estimated 296 million people worldwide had chronic hepatitis
B infection and 58 million are currently estimated to have chronic hepatitis C, with 1.5 million new infections of both hepatitis
B and C, occurring annually. With the help of latest serological biomarkers and viral nucleic acid amplification tests, it has become
rather simple to efficiently screen, diagnose and monitor patients with hepatitis, and to commence with appropriate antiviral
treatment. More importantly, the development of vaccinations against some of these viruses has greatly helped to curb the infection
rates. Whilst there has been exceptional progress over the years in the management of viral hepatitis, many hurdles still remain
which must be addressed in order to proceed towards a hepatitis-free world. This review will shed light on the origin and discovery
of the hepatitis viruses, the global epidemiology and clinical symptoms, diagnostic modalities, currently available treatment
options, the importance of prevention, and the journey needed to move forward towards the eradication of its global disease
burden.
Keywords: prevention, diagnosis, management, liver, infection, viral structure

Introduction
Inflammation of the liver parenchyma in response to viral infections is called viral hepatitis. The hepatotropic viruses
including hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and hepatitis E (HEV) make up
the majority of such infections. Globally, millions of people are affected by these viruses annually.1 The clinical spectrum
of disease ranges from asymptomatic to acute hepatitis, acute liver failure, chronic liver disease, and even the development of hepatocellular carcinoma in some proportion of patient.2,3
An estimated two billion people have been infected with HBV, with 296 million being chronic carriers of HBV and
58 million being chronic carriers of HCV.4,5 In endemic areas, most children are infected with viral hepatitis caused by
HAV, at an early age.6 The annual death rate by viral hepatitis is 1.4 million, with HBV and HCV being the main culprits,
contributing to 90% of mortalities.1
Effective treatment and eradication of viral hepatitis involves a thorough understanding and education, about the
origin of these viruses, diagnosis, treatment, and preventative approaches required. This review highlights the global
epidemiology, currently available treatments, preventative strategies to combat viral hepatitis, and the journey remaining
towards the eradication of its global disease burden. Table 1 summarizes the key points regarding the hepatotropic
viruses.
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ssRNA

dsDNA

ssRNA

ssRNA

ssRNA

1973

1965

1989

1977

1990

296 million4

58 million4

60 million82

20 million96

Parenteral107

Parenteral107

Oro-fecal107

Type of Virus
Discovery
Global Prevalence

• 1.4 million cases per year106

Malik et al

14

Table 1 Comparison of Hepatitis Viruses

• Occurs in epidemics
Oro-fecal107

Transmission

• Parenteral107
• Vertical
• Sexual

Incubation Period

2–6 weeks107

4–26 weeks107

2–26 weeks107

4–26 weeks107

2–8 weeks107

No

Yes

Yes

Yes

No (may be seen in immunodeficiency
states)

Chronic State

Clinical Symptoms

• May be asymptomatic
• Symptoms may include:

• May be asymptomatic
• Symptoms may include:

• Asymptomatic
• Very rarely, symptoms occur in acute

Co-infection: Mirrors
HBV

infection

• May be asymptomatic
• Symptoms may include:

- Fever

- Fever

Super infection:

- Fever

- Fatigue
- Jaundice

- Fatigue
- Jaundice

• May be asymptomatic
• Symptoms may

- Fatigue
- Jaundice

- Nausea

- Nausea

include:

- Nausea

- Vomiting
- Anorexia

- Vomiting
- Anorexia

- Fever
- Fatigue

- Vomiting
- Anorexia

- Jaundice

- Anorexia
Laboratory

Anti-HAV IgM antibodies107

Diagnosis

• HBsAg detection107
• HBcAg antibodies

• Anti-HCV antibodies107
• HCV RNA PCR

• HBV DNA PCR
Treatment

Prevention

Supportive

• Anti-HDV
antibodies

107

• Anti-HEV antibodies107
• HEV RNA PCR

• HDV RNA PCR

• Supportive

• Supportive

• Supportive

• Anti-viral therapy

• Anti-viral therapy

• Anti-viral therapy

Supportive

• HAV Vaccine

• HBV Vaccine

• Screening

• HBV Vaccine

• HEV Vaccine

• Improving sanitation
• Provision of clean drinking

• Screening
• Educating the public

• Educating the public

• Educating the public

• Improving sanitation
• Provision of clean drinking water

water

• Appropriate disposal of sewage

• Appropriate disposal of sewage
• Educating the public

• Educating the public

Abbreviations: ssRNA, single stranded RNA; dsDNA, double stranded DNA; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HEV, hepatitis E virus; HBsAg, hepatitis B surface antigen;
HBcAg, hepatitis B core antigen; PCR, polymerase chain reaction; IgM, immunoglobulin M; IgG, immunoglobulin G.
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Hepatitis A Virus (HAV)
Discovery
First isolated in 1973, HAV is a small, 27 nm un-enveloped symmetrical RNA virus, initially classified in the genus of
Enteroviruses belonging to the Picornaviridae family.7–9 After the entire nucleotide sequence of the viral genome was
determined, HAV was reclassified as a Hepatovirus.10

Epidemiology and Clinical Symptoms
HAV is contracted via fecal-oral transmission by using contaminated food and water. Millions of individuals live in highrisk conditions to contract HAV viral hepatitis, which is especially true in developing countries. Young children that get
HAV may be asymptomatic. Older children, adolescents, and adults present with fatigue, fever, and/or jaundice, which
lasts for a few weeks before resolution.11 This subset is also at risk of developing acute liver failure and subsequent
death. Globally, the incidence of HAV is reducing with better social awareness about sanitation and hygiene.12 However,
the incidence and prevalence of HAV highly varies from country to country, with socioeconomic status being the major
determinant of the population’s exposure to HAV and its complications.
The likelihood of developing symptoms increases up to 40–50% in the age bracket of 6–14 years and 70–80% in
older age groups.10 Due to virus exposure, host immunity does develop Against HAV, providing long-term immunity
against HAV.13
The main risk factor of HAV transmission in such a population relates to individuals traveling to a country highly
endemic with HAV. Sexually active homosexuals, military personnel, sewage workers, and intravenous drug abusers
(IVDA) are also high-risk groups.14 A major previously noted risk factor is access to sanitary water sources utilized for
toilette purposes, hand washing, drinking water, and food preparation.15,16
After HAV infection, the virus enters into the host bloodstream through the intestine and targets the liver parenchyma,
resulting in focal activation of sinusoidal lining and hepatic necrosis with subsequent elevations of aminotransferases.17
During the incubation period, viral replication occurs at its peak which is then excreted into the bile with maximum viral
shedding via feces, whilst the host is asymptomatic.18 It may progress to the icteric phase (lasting up to 2 months or
rarely, with a relapsing and remitting course of 6 months) or non-icteric hepatitis. IgM antibodies are produced within
one week of viral infection.19,20 Levels begin to plateau in 2 months during which long-term protective IgG antibodies
are formed that persist for many years.21

Diagnostic Tests
Various methods for testing HAV include immune electron microscopy, immune adherence heme agglutination, and
radioimmunoassay.7,22 Of these, the most commonly used method includes immune adherence immunoassay. Detection
of serum IgM antibodies against Hepatitis A is the most commonly used diagnostic test whereas, hepatitis A PCR testing
is reserved for a limited number of patients including the immunocompromised.23,24

Management and Prevention
Treatment is symptomatic for the majority of patients, with avoidance of hepatotoxic drugs during the period of active
inflammation within the liver. Rarely it can lead to acute liver failure requiring a liver transplant. As HAV is one of the
leading causes of viral hepatitis, it necessitates the need to provide protective passive immunity against HAV, in the form
of administration of pooled normal human immunoglobulin, at a dose of 100 IU/mL, given intramuscularly.25,26
Administration provides immunity for up to 3–5 months. In the United States, the two available vaccines are inactivated
HAV vaccine HAVRIX (GlaxoSmithKline Biological) and VAQTA (Merck & Company), capable of triggering an
immune response and HAV antibody production.27

Way Forward
HAV vaccine is not freely available in third world countries where this disease is endemic. While vaccination provides
protection efficiently, clean sanitation practices, provision of clean drinking water, and appropriate disposal of human
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waste will ensure eradication of viral spread. Increased awareness, improvement in sanitation, and improved socioeconomic conditions with access to vaccination are important strategies for the future in limiting infection.

Hepatitis B Virus (HBV)
Discovery
Hepatitis B was first discovered in 1965 by Dr. Baruch Blumberg.
Hepatitis B is part of the genus Orthohepanaviridae, belonging to the Hepadnaviridae family. The virus is an
enveloped, 42 nm particle identified as the Dane particle, which was first seen via electron microscopy.28

Epidemiology and Pathogenesis
Globally, there are an estimated 296 million cases of chronic hepatitis B with an annual death rate of one million due to
hepatitis B-related complications.29 Hepatitis B can present as acute hepatitis or acute liver failure on one hand whereas,
it can remain asymptomatic and progress to become a chronic liver disease, potentially even leading to hepatocellular
carcinoma in certain patients.3
The journey of the HBV virus into the host cell; the entry, viral replication, and assembly all provide target sites for
new drug therapies.

Viral Structure and Encoding
Hepatitis B is a partially double-stranded DNA virus. Its DNA exists in a relaxed, circular, partially double-stranded
configuration. It contains four open reading frames, and the morphology allows multiple genes to overlap to use the same
DNA for different viral proteins.
The four genes include core, surface antigen (HBsAg), X, and polymerase gene. Portion X produced by gene X is
responsible for transactivation and possibly hepatocellular carcinoma. Hepatitis B surface antigen (HBsAg) plays an
important role in viral entry, hyposensitization of the adaptive immune system, and is an important parameter in
monitoring response to treatment (HBsAg loss). The core protein formed by gene C is a part of the nucleocapsid
structure of the virus. Along with its structural contribution, the core proteins trigger the formation of hepatitis B core
antibodies.30

Diagnostic Tests
Serological assays are utilized for the diagnosis of hepatitis B virus infection. Hepatitis B surface antigen (HBsAg) is the
most common screening test for hepatitis B, whereas hepatitis B surface antibodies (HBsAb) are used for assessing
immunity post recovery or after vaccination.
Hepatitis B core (HBc) IgM and Hepatitis B core IgG are used to distinguished acute and chronic infections,
respectively. Hepatitis B e Antigen (HBeAg) is a marker of infectivity and usually appears early during the disease
when viral replication is at its peak. In self-limiting causes or after treatment, it can be replaced by antibodies that are
Anti-Hepatitis B e antibodies (HBeAb). When there is pre-core mutation, patients will be Hepatitis e Antigen negative
whilst suffering chronic hepatitis B. Viremia in hepatitis B is assessed by polymerase chain reaction (PCR) which detects
hepatitis B DNA levels.31
Qualitative and quantitative tests for HBV DNA in serum have been developed to assess HBV replication. Currently,
most HBV DNA assays use real-time PCR techniques, report results in international units/mL, have a lower limit of
detection (around 10 to 20 international units/mL) and a range of linearity up to 8 log(10) international units/mL.32
The main challenge in HBV diagnosis is to identify and test people at risk in the community, such as sexual workers
and drug addicts, and patients with occult HBV. This is a condition characterized by the absence of HBsAg in serum, and
presence of HBV DNA by PCR in serum and in the liver.33
Occult HBV has been reported among many high risk groups, including blood donors, liver transplant recipients,
patients co-infected with hepatitis C virus/human immunodeficiency virus and patients undergoing immunosuppressive
therapy.34
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A high index of suspicion is required for its diagnosis and it is recommended to screen with HBV DNA by real-time
PCR periodically, in high risk groups to diagnose and treat these patients in a timely manner.35

Nomenclature of HBV Infection
The interplay of viral replication versus the host immune response against the virus dictates which individual harbors
a chronic infection and which would go on to develop chronic hepatitis (CHB). The new nomenclature describes chronic
HBV infection in two characteristic forms: infection (with no inflammation) versus hepatitis (inflammation).36
The HBV chronic infection in human hosts has been described in five phases. The five phases of HBV infection
include: 1. Patients with HBeAg positivity and high tigers of HBV DNA. Also known as the immune tolerant phase, this
phase usually lasts up to many years, with most patients in this phase having had acquired HBV infection perinatally. An
important concept is that HBeAg, as previously stated, causes reduced sensitivity of the adaptive cytotoxic T (CD8 cells)
and T helper cells (CD4) cells to identify and target HBV infection.37 Thus, these patients have normal to an upper limit
of the normal level of alanine transaminase (ALT). This implies that even in the presence of a high viral load, there is
little parenchymal inflammation and/or necrosis. 2. Phase two defines HBeAg positive chronic hepatitis, previously the
immune clearance phase. This is associated with a high HBV DNA viral load and raised ALT, reflecting moderate to
severe liver inflammation, necrosis, and accelerated healing with fibrosis. 3. Phase three is HBeAg negative chronic
HBV infection with low to normal levels of HBV viral load, normal ALT, and positive HBeAb. 4. HBeAg negative
chronic hepatitis is a reactivation of the inactive state that may be triggered by a superimposed viral infection,
medications, or toxic injury. There is moderate to high HBV viral load, and elevated ALT which define phase four of
hepatitis B. This is associated with histological evidence of fibrosis and liver and ongoing necro-inflammation, with low
chances of spontaneous disease remission. The final phase five is characterized by negative HBsAg, positive anti-HBs,
positive anti-HBc, normal ALT levels, and low to undetectable levels of HBV DNA. This phase is called occult HBV
infection.38,39

Management and Prevention
Interferon-Alpha (IFN-A) and Pegylated Interferon (PEG IFN)
The first drug approved for the treatment of hepatitis B was interferon-a (IFN-A). Its use in treatment for Hepatitis
B dates back to 1976. Interferons are essentially cytokines secreted by dendritic cells in response to parasitic, bacterial,
and viral exposure with a low molecular weight of 15–30 kDa, having anti-viral characteristics. Its main mechanism of
action is triggering cellular mediated immunity. At a nuclear level, IFN-A interferes with transcription mediated by host
RNA polymerase on the cccDNA.
Pegylated interferon-alpha was introduced in 2001, where the active drug is conjugated with polyethylene glycol
molecules that prolong its half-life, allowing only weekly administrations.40–42 Under the current guidelines, Peg IFN-A
is recommended in patients who have HBeAg positive/negative CHB without cirrhosis or selected few patients with
cirrhosis but no portal hypertension. The duration of treatment is 12 months (48 weeks). Patients with decompensated
liver disease may develop flares of hepatitis, thereby making Peg IFN-A a contraindication to therapy in decompensated
cirrhosis.43

Nucleoside/Nucleotide Analogs
The nucleoside analogs are the approved treatment options for CHB patients. Lamivudine, adefovir dipivoxil, and
telbivudine were previously recommended but are now replaced by a high-barrier to resistance drugs, like Tenofovir
disoproxil fumarate, Tenofovir alafenamide, and Entecavir.
Entecavir
Entecavir is a novel deoxyguanosine analog that has antiviral activity against HBV. It is administered at a dose of 0.5mg
once a day. Upon entry into the host cell, the drug gets phosphorylated by host kinases to its active moiety. Its mechanism
of action is halting HBV DNA elongation by the addition of few additional nucleotides.
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In HBeAg positive HBV infection, ETV has a 20% efficacy rate for seroconversion of HBeAg in subjects who are
NA naïve whereas in HBeAg negative patients, HBV DNA undetectable rate is 90% after treatment with ETV.44
Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide
Tenofovir, an acyclic nucleoside phosphonate is an analog of adenosine 5 monophosphate. It hinders the activity of HBV
reverse transcriptase by competing with its natural analog, thus terminating HBV genome replication. There are two
available formulations; tenofovir disoproxil fumarate and tenofovir alafenamide. As it is not metabolized in the liver,
tenofovir can be given in subjects with deranged liver function.
Recent studies have concluded that tenofovir disoproxil fumarate, at a dose of 300 mg OD, is associated with
a higher risk of chronic kidney-related disease, proteinuria, osteoporosis, and bone fractures.45 To overcome its
adversities, a new prodrug- tenofovir alafenamide, has been developed at a dose of 25 mg once daily.
Pharmacodynamics studies have proven that the low concentrations of tenofovir provided by the tenofovir alafenamide
formulation are linked to lesser adverse effects that are seen in the original formulation, with similar efficacy, but better
tolerance.45,46

Treatment Parameters
As described above, hepatitis B exists in 5 recognized phases.
Indication for treatment includes reducing necro-inflammation and subsequent progression to fibrosis, reducing
chances of developing hepatocellular carcinoma and preventing decompensation.47 All patients with an HBV viral load
of >2000 IU/mL, alanine transaminase (ALT) greater than the upper limit of normal, and evidence of necroinflammation on non-invasive fibrosis assessments, or based on histological evidence, warrant treatment.42
Additionally, patients with a high viral load of >20,000 IU/mL, with ALT 2 times the upper limit of normal, regardless
of the level of necro-inflammation require treatment.33,48 Another indication is cirrhosis. Patients with early compensated cirrhosis can be treated with Peg-INF but with decompensation, high barrier resistance agents like TDF/TAF are
preferred.

HBV Vaccination
The most commonly used vaccine is the recombinant hepatitis B vaccines using yeast-derived hepatitis B surface
antigen.49 The recommended regimes are 0, 1, and 6 months. Accelerated doses can be given in 0, 1, and 3 months, with
a booster shot at 12 months.50,51
In November 2017, a new recombinant hepatitis B vaccine designated as HepB-CpG, with a trade name of HeplisavB received approval for use in adults 18 years of age and older. This vaccine consists of recombinant HBsAg with
a novel immunostimulatory adjuvant.52
The vaccine is administered as two intramuscular doses given one month apart. The accelerated regimen used with
this vaccine has the advantage of providing more rapid immune protection and increases the likelihood of completing the
vaccine series. However, data on the use of this vaccine in children, pregnant women, and patients receiving hemodialysis are limited, and this vaccine is not approved for use in these populations.53,54
For most persons, routine postvaccination testing to document anti-HBs seroconversion is unnecessary, since the
recombinant hepatitis B vaccines generally have a response rate of greater than 90%.55
The response rate is lower in obese individuals, smokers, men, and significantly lower in patients with diabetes,
cirrhosis, chronic renal failure, organ transplant recipients, and immunosuppressed patients.56
Routine postvaccination testing is only indicated in this select group of people, or in those with ongoing risk exposure
for example, health care workers and sex partners of HBsAg-positive patients. For such patients, a booster dose is
indicated if anti-HBs declines to less than 10 milli-international units/mL. A positive immune response to vaccination is
defined as the development of hepatitis B surface antibody (anti-HBs) titers greater than 10 milli-international units/
mL.57
When postvaccination testing after the initial series is indicated, it should be performed one to two months after the
last dose. Non-responders to the initial series should complete a second vaccine series.58
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Individuals who fail to respond after a second series are unlikely to benefit from further vaccination, and should be
tested for undiagnosed chronic HBV infection.57
A new generation of recombinant HBV vaccines expressed in mammalian cells containing Pre-S/S epitopes has been
developed in several countries. These are especially useful in high-risk groups and non-responders, as opposed to
conventional HBV vaccines.59 These have been shown to be highly immunogenic, and induce faster and higher
seroprotection rates against HBV with higher anti-HBs levels compared to conventional yeast-derived vaccines. There
is also some evidence to suggest that such Pre-S/S vaccines might be efficacious not only for prevention, but also for
treatment of persistent HBV infection.60

Way Forward
Various emerging drugs like host targeting agents and direct-acting antivirals are under investigation as a potential source
of treating hepatitis B virus infection by affecting cccDNA.

Core Protein Assembly Modulators
These are a new class of antiviral agents that inhibit the assembly of core proteins around the viral genome to form the
nucleocapsid. The assembly of core proteins is inhibited so viral replication cannot occur. There is thus, the production of
empty capsids.61,62
ABI-H0731 is an investigational inhibitor of the HBV core protein. In randomized, placebo-controlled Phase 1 and 2
studies, the drug has been effective in viral suppression in a dose dependent manner.
GSK3228836 is an antisense oligonucleotide targeting HBV RNA. It is currently under investigation in an open-label
single-arm exploratory study in patients with HBeAg negative CHB.

Entry Inhibitors
HBV and HDV gain entry into hepatocytes via NTCP receptors. Bulevirtide (Myrcludex-B) is a novel entry inhibitor.
Studies conducted have shown a decline in HBV viral load, however, the agent has minimal effect on hepatocytes already
harboring the virus making it less efficacious for monotherapy. Thus, it is considered to be a synergistic agent with other
antiviral medications.

cccDNA Silencing
After the HBV virus gains entry into hepatocytes, the genome enters into the nucleus in its relaxed circular DNA form,
where it is subsequently converted to covalently-closed circular DNA form (cccDNA). Zinc finger nucleases are known
to inhibit this conversion, epigenetically modify cccDNA, and degrade it. It remains an attractive upcoming class of
antiviral due to its capability of reducing cccDNA.63
VIR-2218 is an investigational GalNAc-conjugated small interfering ribonucleic acid (siRNA), which is capable of
targeting region X of the HBV genome, thus halting transcription from the integrated HBV DNA and the cccDNA.63
PreS1-polypeptide vaccination presents strong immunogenicity for both B-cell and T-cell responses. Studies in mice
models demonstrated that the new anti-PreS1 is capable of clearing HBV DNA in carrier mice and prevents infection of
healthy cells.
Thus, the future may bring many Medicines that may enable a cure for HBV.

Hepatitis C Virus
Discovery
The Center for Disease Control and California Biotechnology Company had first discovered the non-A non-B hepatitis
(NANBH) later named Hepatitis C. Its genome was identified soon after as a single-stranded RNA.64

Epidemiology and Pathogenesis
HCV binds to the host cell receptors and enters the cell via clathrin-mediated endocytosis. The viral genome is liberated
from its envelope during endocytosis and the single-stranded positive polarity RNA enters into the cytoplasm where the
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RNA acts as a template for protein translation. NS3, NS4, NS5A and NS5B are nonstructural proteins which are
important sites for therapeutic actions of the new direct-acting antiviral drugs.65
The World Health Organization had created a Global Hepatitis Strategy in 2015 that aimed to eliminate viral hepatitis
by 2030 with a reduction in incidence by 90%, and a 65% reduction in mortality. However, even with the advent of new
direct-acting antivirals (DAAs), developing countries face little chance of reaching the goals of the Global Hepatitis
strategy by 2030, as only a few countries have granted coverage for DAAs.66,67 Egypt is the only developing country of
the 9 countries, that are aimed to achieve this target by 2030.
Furthermore, with the use of injectable drugs on the rise, especially amongst the young population, the prevalence of
HCV is further increasing. The majority of these injectable drug users remain undiagnosed and represent a major
proportion of the high-risk individuals, who continue to spread infection and contribute to the global disease burden.68,69

Diagnostic Tests
Immunoassay for antibodies against HCV (anti-HCV) is the test of choice for diagnosis and screening of HCV patients.
Anti-HCV positivity suggests ongoing or past infection. The next step for confirming the diagnosis is HCV RNA testing
via polymerase chain reaction (PCR). Previously, genotyping was important but now it is not necessary in most cases
after the advent of pan-genotypic DAAs.
It is important however, to note that there is an estimated 56–70 day “window period”, in which antibody titers may
not be detectable. To overcome this hurdle and detect infection earlier on, HCV core antigen (HCVcAg) quantification
assay has also been developed as a marker of infection, which has a high clinical sensitivity and is relatively inexpensive.
However, it’s use is limited as only few research centres have it available and HCV RNA detection remains the goldstandard in confirming HCV infection in clinical practice.70,71

Management and Prevention
The main goal of HCV therapy is to achieve undetectable HCV-RNA in serum. Initial management regimes included
Peg-INF and Ribavirin. However, treatment was characterized by poor success rates, and adverse effects.72
In 2015, multiple direct-acting antivirals emerged that revolutionized HCV treatment. There are four classes of drugs
that are classified according to their target protein. These include NS3/4a protease inhibitors, NS5B nucleoside polymerase inhibitors, NS5B non-nucleoside polymerase inhibitors (NNPIs), and NS5A inhibitors.73
NS3/4a are proteases involved in post-translational modifications of the newly synthesized polyprotein.74 NS5A plays
a role in the organization of the replication complex and assembling the virion before its cellular exit.75 Nonstructural
protein 5B (NS5B) is a viral protein that is an RNA-dependent RNA polymerase, thus essential for HCV viral
replication.76 Sofosbuvir is the first NS5B nucleoside polymerase inhibitor available. Other newer agents are
Glecaprevir, Grazoprevir, and Paritaprevir. NS5A inhibitors include Pibrentasvir and Elbasvir.77
Other NS5A’s are used in combination with Sofosbuvir, including Sofosbuvir and Velpatasvir, and Sofosbuvir and
Ledipasvir. Both these combinations can be given in cirrhosis regardless of severity, but due to the excreted metabolite of
Sofosbuvir that is GS 331007, their use is limited in patients with an eGFR <30.78
The development of pan-genotypic combination DAAs have revolutionized HCV treatment – the need for pegylated
interferon has been removed and the use of ribavirin and need for virological testing services, have considerably reduced.
Whilst these combination therapies have simplified treatment to a great deal, some genotypes (such as genotype 3), still
require adjustment in the selection of agents, duration of treatment and the need for adjuvant ribavirin. It is therefore,
important for national health authorities to select specific combination therapies, based on the regional genotypic
prevalence to overcome the aforementioned constraints, in addition to some baseline resistance polymorphisms.
Furthermore, these treatment regimens are relatively costly making widespread accessibility and affordability in developing countries limited, which poses yet another constraint.79
Whilst pharmacological therapy remains the definitive management, it is also imperative to educate the population
about the transmission of HCV infection, as a lack of awareness has most commonly been associated with spread of
disease. High-risk individuals should be preferentially screened, and latest anti-HCV medications should be made easily
available.68,69
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Way Forward
Pan-genotypic DDAs are a treatment of choice for HCV with excellent efficacy. Active screening and treatment along
with educating people regarding preventive measures are the need of the hour, especially for third world countries. These
measures will help to achieve the WHO aims of eliminating viral hepatitis by 2030.

Hepatitis D Virus (HDV)
Discovery
HDV was first discovered by Rizetto, in 1977 and it is a 30–35 nm, circular, and covalently-closed single-stranded RNA
virus.80,81

Epidemiology and Pathogenesis
An estimated 60 million people are infected with HDV globally.82 It is a defective virus that does not synthesize its
envelope proteins, thus requiring the HBV surface antigen in the host cells to complete its replication. HDV is capable of
entering into hepatocytes and replicating its genome. It is however, unable to release its virions without the simultaneous
co-infection with HBV.83
Simultaneous HDV and HBV co-infection manifests as acute hepatitis, with fever, nausea, vomiting, and jaundice.84
There is a biphasic increase in aminotransferase, with an initial peak due to HBV replication and the second peak due to
HDV viremia.85 Another manifestation is HDV superinfection in an individual who is chronically infected with HBV. In
both scenarios, there lies a risk of acute liver failure.86

Diagnostic Tests
HDV screening is recommended in individuals who are chronically infected with HBV. Anti-HDV antibodies can be
detected with enzyme-linked immunosorbent assays (ELISA) or Rapid immunosorbent assays (RIA), and are available as
IgM and IgG antibodies for the diagnosis of acute or chronic infections, respectively. The test, however, may not be
positive in the initial days-weeks of the infection. HDV RT-PCR remains the confirmatory test of choice. This
distinguishes an ongoing infection from past infections.87,88

Management and Prevention
The goals of therapy for a dual HDV and HBV are similar to the endpoint of treatment for HBV; to achieve a virological
response with undetectable HDV and HBV PCR, with a sustained virological response up to 24 weeks post-treatment.
However, in the case of CHD, relapse rates remain as high as 50% in patients treated with PEG-IFN.
PEG-IFN remains the only recommended treatment for HDV, with a meta-analysis reporting a 25% sustained
suppression of HDV RNA 24 weeks post-treatment. The recommended duration of therapy is 48 weeks.89
Nucleoside/Nucleotide analogs have not proven beneficial in CHD infections, thus not recommended. Preventive
measures and early screening of hepatitis B patients for hepatitis D are important as the only recommended treatment is
PEG-IFN alpha, which can be given predominantly in non-cirrhotic patients only.83

Way Forward
Drugs in the development phase include agents that inhibit crucial steps for viral entry and assembly in the host cells.
Myrcludex B, a myristoylated lipopeptide has a similar N terminal amino acid structure to L-HBsAg, thus is capable of
binding to NCTP and preventing viral entry into the cell.90
Lonafarnib is a farnesylation inhibitor. It prevents farnesylation of L-HDAg, thus inhibiting the assembly of HDV
RNP with HBsAg. Multiple studies have shown a reduction in HDV RNA levels on sorafenib, combined with PEG-IFN
/Ritonavir, but relapse is seen 8 weeks post-treatment.91,92
Various ongoing trials are combing interferon lambda with lonafarnib as well. Nucleic acid polymers and drugs like
ezetimibe are under investigation for the treatment of chronic hepatitis D.93
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HBV vaccines work to protect against HBV and HDV, by reducing the number of individuals at risk of HBV. Currently,
no encouraging results have been demonstrated for vaccines to protect against HDV in HBV-infected individuals.

Hepatitis E (HEV)
Discovery
In 1990, Reyes et al successfully sequenced the Hepatitis E virus genome.94 HEV is a 7.2kB single-stranded positive
polarity RNA virus belonging to the Hepeviridae family.95

Epidemiology and Pathogenesis
Globally hepatitis E is a growing cause of concern as it is one of the leading causes of viral hepatitis. There are at least 4
genotypes that can infect humans. The annual number of recorded cases has been a staggering 20 million with 3.3 million
symptomatic cases and a death toll of 60,000 reported.96 HEV has also remained one of the main factors in causing
maternal and fetal mortality during pregnancy, and around 15–60% of acute hepatitis E infection progresses to acute liver
failure in pregnant patients in developing countries.97,98 In Iran, epidemiological studies have reported seropositivity
between 3.6 to 7.4% amongst pregnant women, depending upon the geographical location and the level of hygiene in
each area.99
The main source of transmission is the fecal-oral route through contaminated water sources or undercooked meat.
Usually, hepatitis resulting from HEV has a self-limiting course, with an incubation period of 2–8 weeks, and
prodromal symptoms of jaundice, fatigue, nausea, and vomiting. However, chronicity resulting in liver damage and
cirrhosis has been seen in elderly, immunocompromised individuals, and/or HIV-positive individuals.100
An important breakthrough in understanding the variations in HEV clinical manifestations is the genomic mutations.
The HEV genome is a capped virus that attains this character due to the presence of ORF-1 encoded methyltransferase.
A multitude of studies have demonstrated that a mutation in the ORF-1 region for methyltransferase is present in patients
infected with HEV causing acute viral hepatitis or acute liver failure. Paradoxically, single point mutation of H105R
resulted in lower viremia, thus being a possible target of therapy. A G1634R point mutation in RdRp in immunocompromised individuals correlated with higher viremia and resistance to Ribavirin treatment.101

Diagnostic Tests
Detection of Serum IgM antibodies against Hepatitis E is the most commonly used diagnostic test whereas, Hepatitis
E PCR testing is reserved for a limited number of patients including the elderly and immunocompromised.102

Management and Prevention
Symptomatic treatment for the majority of patients and avoidance of hepatotoxic drugs will lead to full recovery but
during pregnancy, chances of acute liver failure are more and close monitoring is mandatory for such patients. Rarely
genotypes 3 and 4 can lead to chronic infection especially in the elderly and immunocompromised individuals. Ribavirin
has a role in the treatment of hepatitis E in immunocompromised patients.103,104

Way Forward
HEV vaccine is not readily available in the world but Hecolin is a commercially available approved hepatitis E vaccine in
China with promising control of epidemic and sporadic hepatitis E cases. The way forward will be similar to HAV as the
mode of spread is the same. Improving sanitation, educating the public, providing HEV vaccination and perhaps even
including this in pediatric vaccination programs, will help us to control and eradicate this disease.105

Conclusion
Viral hepatitis continues to harbor a significant global health burden and a fundamental understanding of its structural,
epidemiological and clinical features are imperative in the fight to eradicate the disease. Efficient and risk-based
screening programs, combined with advanced diagnostic modalities allow prompt recognition of infection and early
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initiation of treatment, thereby controlling disease transmission. With continuous progress in anti-viral therapies available, the challenge of tackling this ubiquitous infection has greatly reduced however, efforts towards prevention such as
vaccination, remain the first-step and are of paramount importance. It is through these key measures, and the establishment of global health policies that sanction widespread accessibility to the latest diagnostic tests and therapeutic drugs,
that we can achieve our goal of a hepatitis-free world.
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